Determination of docetaxel and paclitaxel in human plasma by high-performance liquid chromatography: Validation and application to clinical pharmacokinetic studies

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 199-205

  López, Laura Zufía ^a   Pastor, Azucena Aldaz ^a   Aramendia Beitia, Jose Manuel ^a   Velilla, Juncal Arrobas ^a   Deiró, Joaquín Giraldez ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

HPLC; Pharmacokinetic; Taxanes; Validation

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ISOLATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HALF-LIFE; HUMANS; PACLITAXEL; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TAXOIDS; TEMPERATURE;

EID: 33748175492     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000189903.46802.1f     Document Type: Article

References (46)

1. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res. 1991;51:4845-4852.
2. Wall ME, Wani MC, Taylor HL, et al. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325-2327.
3. Gueritte-Voegelein P, Guenard D, Lavelle F, et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem. 1991;34:992-998.
4. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analog of Taxol. J Natl Cancer Inst. 1991;83:288-291.
5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature. 1979;277:665-667.
6. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 1980;77:1561-1565.
7. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643-2655.
8. Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55:5-30.
9. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol. 1996;6:443-457.
10. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797-1805.
11. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:384-388.
12. Kohler DR, Goldspiel BR. Paclitaxel (Taxol). Pharmacotherapy. 1994;14:3-34.
13. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (Docetaxel). Cancer Surv. 1993;17:305-313.
14. Rowinsky EK. Paclitaxel pharmacology and other tumor types. Semin Oncol. 1997;24:S19-1-S19-12. [Review]
15. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol. 1995;22(Suppl 6):16-23.
16. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24 hour infusion. Clin Cancer Res. 1995;1:599-606.
17. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel in a dose-escalating and dose sequencing study in patients with non-small-cell lung cancer. J Clin Oncol. 1997;15:317-329.
18. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180-190.
19. Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000;6:1255-1258.
20. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99.
21. Hempel G, Lehmkuhl D, Krumpelmann S, et al. Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography. J Chromatogr A. 1996;745:173-179.
22. BitschWenwen F, McDonald F, NiederCedric M. Analysis of Taxol and related diterpenoids from cell cultures by liquid chromatography-electrospray mass spectrometry. J Chromatogr. 1993;615:273-280.
23. Poon GK, Wade J, Bloomer J, et al. Rapid screening of Taxol metabolites in human microsomes by liquid chromatography/electrospray ionization-mass spectrometry. Rapid Commun Mass Spectrom. 1996;10:1165-1168.
24. Leu JG, Chen BX, Schiff PB, et al. Characterization of polyclonal and monoclonal antitaxol antibodies and measurement of Taxol in serum. Cancer Res. 1993;53:1388-1391.
25. Svojanovsky ST, Egodage KL, Wu J, et al. High sensitivity ELISA determination of Taxol in various human biological fluids. J Pharm Biomed Anal. 1999;20:549-555.
26. Rizzo J, Riley C, von Hoff D, et al. Analysis of anticancer drugs in biological fluids: determination of Taxol with application to clinical pharmacokinetics. J Pharm Biomed Anal. 1990;8:159-164.
27. Verginol JC, Bruno R, Montay G, et al. Determination of taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr. 1992;582:273-278.
28. Ardiet CJ, Tranchand B, Zanetta S, et al. A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics. Invest New Drugs. 1999;17:325-333.
29. Loos WJ, Verweij J, Nooter K, et al. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997;693:437-441.
30. Song D, Au JLS. Isocratic high-performance liquid chromatographic assay of Taxol in biological fluids and tissues using automated column switching. J Chromatogr B Biomed Sci Appl. 1995;663:337-344.
31. Huizing MT, Rosing H, Koopman F, et al. High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine. J Chromatogr B Biomed Sci Appl. 1995;664:373-382.
32. Sparreboom A, de Bruijn P, Nooter K, et al. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;705:159-164.
33. El-Yazigi A, Yusuf A. Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. Ther Drug Monit. 1995;17:511-515.
34. Grem JL, Tutsch KD, Simon KJ, et al. Phase I study of Taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep. 1987;71:1179-1184.
35. Longnecker SM, Donehower RC, Cates AE, et al. High-performance liquid chromatographic assay for Taxol (NSC125973) in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep. 1987;71:53-59.
36. Sparreboom A, van Tellingen O, Nooijen WJ, et al. Preclinical pharmacokinetics of paclitaxel and docetaxel: a review. Anticancer Drugs. 1998;9:1-16.
37. Rouini MR, Lotfolahi A, Stewart DJ, et al. A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. J Pharm Biomed Anal. 1998;17:1243-1247.
38. Supko JG, Nair RV, Seiden MV, et al. Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma. J Pharm Biomed Anal. 1999;21:1025-1036.
39. Sottani C, Minoia C, D'Incalci M, et al. High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma. Rapid Commun Mass Spectrom. 1998;12:251-255.
40. Sottani C, Turci R, Micoli G, et al. Rapid determination of paclitaxel (Taxol) in environmental samples by high-performance liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom. 2000;14:930-935.
41. Alexander MS, Kisser MM, Culley T, et al. Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasma. J Chromatogr B Biomed Sci Appl. 2003;785:253-261.
42. Parise RA, Ramanathan RK, Zamboni WC, et al. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Biomed Sci Appl. 2003;783:231-236.
43. Baker SD, Zhao M, He P, et al. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem. 2004;324:276-284.
44. US FDA. Guidance for industry: bioanalytical method validation. Rockville, MD: (CDER), May 2001. Available at: http://ww.fda. gov/eder/guidance/index.htm. Date accessed.
45. Baille P, Bruno R, Schellens JH, et al. Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res. 1997;3:1535-1538.
46. Rosing H, Lusting V, Koopman FP, et al. Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B Biomed Sci Appl. 1997;696:89-98.